Antineoplastic Agents: Cytotoxic Agents: Antitumor Antibiotics
IADRI1 “Adriblastina injection” 10 mg/vial
ILIPO1 “Lipo-dox liposome injection” 10 mg/vial
適應症：
IADRI1：急慢性白血球過多症、硬瘤、淋巴瘤、軟纖維性肉瘤、交感神經母細胞瘤、乳癌、肺癌。
ILIPO1：用於治療1.CD4數量低下（<200 CD4 lymphocytes/mm3）和黏膜、皮膚或內臟有病變的AIDS related kaposi’s sarcoma的病人；2.用於治療曾接受第一線含platinum及paclitaxel化學治療而失敗者，或再復發之進行性或轉移性卵巢癌病人；3.可用於單一治療有心臟疾病風險考量之轉移性乳癌患者。
Usual dose:
AIDS-related Kaposi’s sarcoma: 20 mg/m2 IV over 30 min q3w.
Ovarian cancer: 50 mg/m2 IV over 1 h q4w.
Multiple myeloma: 40 mg/m2 IV in combination with vincristine and dexamethasone.
Dose adjustment:
Hepatic impairment: 50% dose reduction for serum bilirubin of 1.2 to 3 mg/dL; 75% dose reduction for serum bilirubin of 3.1 to 5 mg/dL.
Adverse effect:
Common: abdominal pain, constipation, diarrhea, alopecia.
Serious: myelosuppression, cardiomyopathy, infusion reactions, palmar-plantar erythrodysesthesia, rash, stomatitis.
健保使用規範：(91/3/1、93/8/1、93/11/1、99/10/1)
限用於下列適應症: (99/10/1)
- 用於治療曾接受第一線含platinum及paclitaxel化學治療而失敗者或再復發之進行性或轉移性卵巢癌病人。(91/3/1)
- 用於治療CD4數量低下（< 200 CD4 lymphocyte/mm3）和粘膜、皮膚或內臟有病變的AIDS related Kaposi’s Sarcoma的病人。(91/3/1)
- 用於單一治療有心臟疾病風險考量之轉移性乳癌患者。(93/11/1)